Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GSK3B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GSK3B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GSK3B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GSK3B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GSK3B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GSK3B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GSK3B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GSK3B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GSK3B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GSK3B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GSK3B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00320919 | Oral cavity | OSCC | negative regulation of protein binding | 57/7305 | 94/18723 | 1.75e-05 | 1.71e-04 | 57 |
GO:003011110 | Oral cavity | OSCC | regulation of Wnt signaling pathway | 165/7305 | 328/18723 | 1.87e-05 | 1.80e-04 | 165 |
GO:001081120 | Oral cavity | OSCC | positive regulation of cell-substrate adhesion | 71/7305 | 123/18723 | 1.96e-05 | 1.87e-04 | 71 |
GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
GO:003133318 | Oral cavity | OSCC | negative regulation of protein-containing complex assembly | 79/7305 | 141/18723 | 3.01e-05 | 2.76e-04 | 79 |
GO:00082868 | Oral cavity | OSCC | insulin receptor signaling pathway | 67/7305 | 116/18723 | 3.23e-05 | 2.91e-04 | 67 |
GO:00973459 | Oral cavity | OSCC | mitochondrial outer membrane permeabilization | 24/7305 | 32/18723 | 3.83e-05 | 3.37e-04 | 24 |
GO:000762316 | Oral cavity | OSCC | circadian rhythm | 110/7305 | 210/18723 | 5.40e-05 | 4.48e-04 | 110 |
GO:190204115 | Oral cavity | OSCC | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 33/7305 | 49/18723 | 5.49e-05 | 4.54e-04 | 33 |
GO:19026868 | Oral cavity | OSCC | mitochondrial outer membrane permeabilization involved in programmed cell death | 28/7305 | 40/18723 | 7.00e-05 | 5.60e-04 | 28 |
GO:19019843 | Oral cavity | OSCC | negative regulation of protein acetylation | 19/7305 | 24/18723 | 7.18e-05 | 5.67e-04 | 19 |
GO:19057107 | Oral cavity | OSCC | positive regulation of membrane permeability | 32/7305 | 48/18723 | 9.60e-05 | 7.25e-04 | 32 |
GO:005110019 | Oral cavity | OSCC | negative regulation of binding | 87/7305 | 162/18723 | 1.00e-04 | 7.54e-04 | 87 |
GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:000195416 | Oral cavity | OSCC | positive regulation of cell-matrix adhesion | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
GO:00059968 | Oral cavity | OSCC | monosaccharide metabolic process | 129/7305 | 257/18723 | 1.63e-04 | 1.13e-03 | 129 |
GO:005134618 | Oral cavity | OSCC | negative regulation of hydrolase activity | 182/7305 | 379/18723 | 1.98e-04 | 1.32e-03 | 182 |
GO:19038288 | Oral cavity | OSCC | negative regulation of cellular protein localization | 65/7305 | 117/18723 | 2.05e-04 | 1.36e-03 | 65 |
GO:004346716 | Oral cavity | OSCC | regulation of generation of precursor metabolites and energy | 71/7305 | 130/18723 | 2.15e-04 | 1.41e-03 | 71 |
GO:19021107 | Oral cavity | OSCC | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 26/7305 | 38/18723 | 2.29e-04 | 1.49e-03 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3B | SNV | Missense_Mutation | | c.46N>T | p.Pro16Ser | p.P16S | P49841 | protein_coding | tolerated_low_confidence(0.36) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | novel | c.857C>G | p.Pro286Arg | p.P286R | P49841 | protein_coding | deleterious(0.03) | benign(0.162) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
GSK3B | insertion | Nonsense_Mutation | novel | c.1146_1147insGAAACCGGGAGGCGGAGGTTGCATTGAGCCGAGATTGCGCC | p.Asn383GlufsTer9 | p.N383Efs*9 | P49841 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
GSK3B | insertion | In_Frame_Ins | novel | c.44_45insATCACAAGGAGAACTCTGTTTTGA | p.Lys15_Pro16insSerGlnGlyGluLeuCysPheGlu | p.K15_P16insSQGELCFE | P49841 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | deletion | Frame_Shift_Del | novel | c.850delN | p.Met284Ter | p.M284* | P49841 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
GSK3B | SNV | Missense_Mutation | novel | c.259G>A | p.Val87Ile | p.V87I | P49841 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | novel | c.683N>A | p.Ile228Asn | p.I228N | P49841 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | rs72548709 | c.995N>A | p.Arg332His | p.R332H | P49841 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | | c.713N>C | p.Ile238Thr | p.I238T | P49841 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GSK3B | SNV | Missense_Mutation | | c.901T>C | p.Trp301Arg | p.W301R | P49841 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PMID26161698-Compound-18 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | Neu-120 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | SOTRASTAURIN | SOTRASTAURIN | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CYC-116 | CYC-116 | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | tideglusib | TIDEGLUSIB | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 404859135 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALSTERPAULLONE | ALSTERPAULLONE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL1200826 | LITHIUM CARBONATE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | AMO-02 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BETULINIC ACID | BETULINIC ACID | 19716700 |